Biotech Values

[jbog]

I thought the GS was very informative. Of course our main contention with the report was the fair value of Momenta at this point.

I can't say I can argue with GS's determination if I consider the potential brick wall. Now it's up to Momenta's management to carry the ball forward.

Momenta itself hasn't done us any favors when you add together the rampant insider sales, the new stock issue, the retirement of two key people and the teva lawsuit.

It's funny when we blame Goldman for pointing out the clouds overhanging this stock while it is management who are seeding them.